£4m project starts on schizophrenia drug at the University of Sussex

£4m project starts on schizophrenia drug

£4m project starts on schizophrenia drug

First published in News

Scientists are starting work today on a £4 million project to develop a new drug to treat schizophrenia.

The team at the University of Sussex are hoping to have a compound ready for clinical testing in just over three years.

The project, run by the the university’s Translational Drug Discovery Group, is funded by the Wellcome Trust.

About 1% of the population will suffer from schizophrenia at some point in their life.

The condition, which often affects people in their late teens and early twenties, has symptoms such as paranoia, hearing voices, problems with thought processes and an inability to function socially.

Current treatments are good at suppressing delusional episodes by blocking the brain’s dopamine receptors but they have little effect on the other symptoms.

These can make it hard for people with the condition to lead a “normal” life.

The Sussex team is taking a new approach by looking at another of the brain’s key chemicals, glutamate, which is associated with attention, memory and problem solving.

They hope to help the brain compensate for problems with the chemical and improve thought processes.

Lead scientist Simon Ward said: “Schizophrenia is often a devastating condition for the sufferers, their families and communities. The challenge is in designing a compound that will have just the right effect.”

Comments (1)

Please log in to enable comment sorting

12:24pm Fri 1 Aug 14

PaulOckenden says...

I'm in two minds about this...
I'm in two minds about this... PaulOckenden
  • Score: -2

Comments are closed on this article.

Send us your news, pictures and videos

Most read stories

Local Info

Enter your postcode, town or place name

About cookies

We want you to enjoy your visit to our website. That's why we use cookies to enhance your experience. By staying on our website you agree to our use of cookies. Find out more about the cookies we use.

I agree